KRX Growth Companies With Minimum 12% Insider Ownership
The South Korean market has shown robust performance recently, with a 2.8% increase over the last week and a 9.4% rise over the past year, alongside expectations of significant earnings growth at an annual rate of 30%. In this context, stocks like those of growth companies with high insider ownership can be particularly interesting to investors looking for aligned interests between company management and shareholders.
Top 10 Growth Companies With High Insider Ownership In South Korea
Name | Insider Ownership | Earnings Growth |
ALTEOGEN (KOSDAQ:A196170) | 26.6% | 73.1% |
Global Tax Free (KOSDAQ:A204620) | 18.1% | 72.4% |
Seojin SystemLtd (KOSDAQ:A178320) | 27.9% | 58.7% |
Fine M-TecLTD (KOSDAQ:A441270) | 17.3% | 36.4% |
Park Systems (KOSDAQ:A140860) | 33% | 35.6% |
Vuno (KOSDAQ:A338220) | 19.5% | 105% |
UTI (KOSDAQ:A179900) | 34.1% | 122.7% |
HANA Micron (KOSDAQ:A067310) | 20% | 96.3% |
INTEKPLUS (KOSDAQ:A064290) | 16.3% | 77.4% |
Techwing (KOSDAQ:A089030) | 18.7% | 77.8% |
Let's review some notable picks from our screened stocks.
ALTEOGEN
Simply Wall St Growth Rating: ★★★★★★
Overview: ALTEOGEN Inc. is a biopharmaceutical company specializing in the development of long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars, with a market capitalization of approximately ₩14.32 billion.
Operations: The company specializes in three primary revenue segments: long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars.
Insider Ownership: 26.6%
ALTEOGEN, a South Korean biotech, is experiencing robust growth with its recent MFDS approval of Tergase®, a highly pure recombinant hyaluronidase. This approval could extend product applications beyond traditional markets. Financially, ALTEOGEN's revenue is growing at 48.3% annually, outpacing the local market's 10.8%. Earnings are also expected to surge by 73.1% annually over the next three years, significantly above market forecasts. Despite high volatility in its share price and no recent insider trading data, the company's strategic advancements and financial projections indicate strong future potential.
ST PharmLtd
Simply Wall St Growth Rating: ★★★★☆☆
Overview: ST Pharm Co., Ltd. specializes in custom manufacturing services for active pharmaceutical ingredients and intermediates, operating both in South Korea and internationally, with a market capitalization of approximately ₩1.84 billion.
Operations: The company generates ₩251.86 billion from raw drug manufacturing and ₩34.40 billion from clinical trial site consignment research institute services.
Insider Ownership: 13%
ST PharmLtd, a South Korean pharmaceutical company, is poised for substantial growth with earnings forecasted to increase by 34.16% annually, outstripping the broader market's 29.7%. Despite trading at 57.8% below its estimated fair value and a forecasted low return on equity of 13.1% in three years, the firm shows promise with revenue expected to grow by 16.5% per year, again surpassing market averages. However, shareholder dilution over the past year and high share price volatility may pose challenges.
Click here and access our complete growth analysis report to understand the dynamics of ST PharmLtd.
Doosan
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Doosan Corporation operates in heavy industry, machinery manufacturing, and apartment construction across South Korea, the U.S., Asia, the Middle East, and Europe with a market cap of approximately ₩3.76 billion.
Operations: The company's revenue is derived from its involvement in heavy industry, machinery manufacturing, and apartment construction across various global regions.
Insider Ownership: 38.9%
Doosan Corporation, a South Korean entity, has shown a remarkable turnaround with its first quarter earnings for 2024, reporting KRW 180.97 billion in sales and a net income of KRW 4.98 billion after a significant loss the previous year. Despite this positive shift and expectations to become profitable within three years, its revenue growth at 3.6% annually lags behind the market's 10.8%. Additionally, while forecasted to have high return on equity at 22.2%, Doosan faces challenges with highly volatile share prices and trades at 56% below its estimated fair value.
Take a closer look at Doosan's potential here in our earnings growth report.
The valuation report we've compiled suggests that Doosan's current price could be quite moderate.
Seize The Opportunity
Click here to access our complete index of 82 Fast Growing KRX Companies With High Insider Ownership.
Hold shares in these firms? Setup your portfolio in Simply Wall St to seamlessly track your investments and receive personalized updates on your portfolio's performance.
Simply Wall St is a revolutionary app designed for long-term stock investors, it's free and covers every market in the world.
Want To Explore Some Alternatives?
Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
Find companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.
Companies discussed in this article include KOSDAQ:A196170 KOSDAQ:A237690 and KOSE:A000150.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com